Profile: Novartis AG (NVS.N)
2 Dec 2016
Novartis AG, incorporated on March 1, 1996, is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company's segments include Pharmaceuticals, which researches, develops, manufactures, distributes and sells prescription medicines in the therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience and established medicines; Alcon, which operates through over three franchises: Surgical, Ophthalmic Pharmaceuticals and Vision Care, and Sandoz, which develops, manufactures and markets generic pharmaceutical products, follow-on biopharmaceutical products known as biosimilars, and other drug substances.
The Pharmaceuticals segment is organized into global business franchises responsible for the commercialization of various products. Its Pharmaceuticals segment also has a unit focused on the development and commercialization of Cell and Gene Therapies. The Pharmaceuticals segment sells products in approximately 160 countries around the world.
The Company's Oncology products include Afinitor/Votubia, Exjade, Jakavi, Sandostatin SC and Sandostatin LAR, Signifor and Signifor LAR, Femara, Zometa, Tasigna and Gleevec/Glivec, among others. Gleevec/Glivec is a kinase inhibitor, which is used to treat patients with metastatic and/or unresectable KIT (CD117) positive (KIT+) gastrointestinal stromal tumors (GIST), as an adjuvant treatment for adult patients' resection of KIT+ GIST, and as a targeted therapy for Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). Afinitor/Votubia and Afinitor Disperz/Votubia (everolimus) is an oral inhibitor of the mTOR pathway. Tasigna (nilotinib) is a signal transduction inhibitor of the BCR-ABL tyrosine kinase. Sandostatin SC and Sandostatin LAR (octreotide acetate/octreotide acetate for injectable suspension) is a somatostatin analogue indicated for the treatment of patients with acromegaly, a chronic disease caused by over-secretion of pituitary growth hormone in adults. Sandostatin is also indicated for the treatment of patients with certain symptoms associated with carcinoid tumors and other types of gastrointestinal and pancreatic neuroendocrine tumors.
The Company's Exjade (deferasirox) is an iron chelator, which is used for the treatment of chronic iron overload due to blood transfusions in patients over two years of age and older. Zometa (zoledronic acid) is used in an oncology setting to reduce or delay skeletal-related events, including pathologic fracture, spinal cord compression, and/or requirement of radiation therapy or surgery to bone, in patients with bone metastases (cancer that has spread to the bones) from solid tumors and multiple myeloma. Votrient (pazopanib) is a small molecule tyrosine kinase inhibitor that targets a number of intracellular proteins to limit tumor growth and cell survival. Tafinlar + Mekinist (dabrafenib + trametinib) is indicated for the treatment of patients with BRAF V600 mutation positive unresectable or metastatic melanoma. Jakavi (ruxolitinib) is an oral inhibitor of the JAK1 and JAK2 tyrosine kinases. Promacta/Revolade (eltrombopag) is an oral thrombopoietin (TPO) receptor agonist that works by stimulating bone marrow cells to produce platelets. Farydak (panobinostat) is a histone deacetylase (HDAC) inhibitor indicated, in combination with bortezomib and dexamethasone, for the treatment of adult patients with relapsed and/or refractory multiple myeloma. Odomzo (sonidegib) is a selective smoothened inhibitor available in the United States for the treatment of adult patients.
The Company's Cardio-Metabolic product includes Galvus and Entresto. Galvus (vildagliptin), an oral DPP-4 inhibitor, and Eucreas, a single-pill combination of vildagliptin and metformin, are indicated for the treatment of type 2 diabetes. Galvus is available in approximately 130 countries, including European Union member states, Japan and countries in Latin America and Asia-Pacific. Entresto (sacubitril/valsartan) is an angiotensin receptor/neprilysin inhibitor indicated for the treatment of chronic heart failure with reduced ejection fraction (HFrEF).
The Company's Immunology and Dermatology products include Neoral, Myfortic, Zortress/Certican, Ilaris, Xolair and Cosentyx. Neoral (cyclosporine, USP Modified) is an immunosuppressant to prevent organ rejection following a kidney, liver, or heart transplant. Neoral is available for use in lung transplant in various countries outside of the United States. This micro-emulsion formulation of cyclosporine is also indicated for treating selected autoimmune disorders, such as psoriasis and rheumatoid arthritis. Myfortic (enteric-coated formulation of mycophenolate sodium) is available in over 90 countries for the prevention of acute rejection of kidney allografts, and is indicated in combination with cyclosporine and corticosteroids. Zortress/Certican (everolimus) is an oral inhibitor of the mTOR pathway, indicated to prevent organ rejection following solid organ transplantation. Ilaris (canakinumab) is a human monoclonal antibody that selectively binds and neutralizes interleukin-1b (IL-1b), a pro-inflammatory cytokine.
Xolair (omalizumab) is available in the European Union, Switzerland and over 40 other countries as a treatment for chronic spontaneous urticaria (CSU)/chronic idiopathic urticaria (CIU). In the European Union, it is used as an add-on therapy for the treatment of CSU in adult and adolescent (12 years and above) patients with inadequate response to H1 antihistamine treatment. In the United States, it is used for the treatment of adults and adolescents (over 12 years of age and above) with CIU when they remain symptomatic despite H1 antihistamine treatment. Cosentyx (secukinumab) is a human monoclonal antibody that selectively neutralizes circulating interleukin 17A (IL-17A).
The Company's Retina product includes Lucentis and Xolair. Lucentis (ranibizumab) is a recombinant humanized high affinity antibody fragment that binds to vascular endothelial growth factors (VEGF). Its Respiratory products include Xolair and Ultibro Breezhaler. Xolair (omalizumab) is the humanized monoclonal antibody approved for the treatment of moderate to severe persistent allergic asthma in the United States in adolescents (aged 12 and above) and adults. Xolair is available in approximately 90 countries, including the United States and the European Union. Ultibro Breezhaler (indacaterol/glycopyrronium bromide)/Utibron Neohaler (indacaterol/glycopyrrolate) is a fixed-dose combination of the long-acting beta2-adrenergic agonist (LABA) indacaterol and the long-acting muscarinic antagonist (LAMA) glycopyrronium bromide.
The Company's Neuroscience products include Gilenya and Exelon. Gilenya (fingolimod) is the oral therapy approved to treat relapsing-remitting multiple sclerosis (RRMS) and a class of compounds called sphingosine 1-phosphate receptor modulators. In the United States, Gilenya is indicated for relapsing forms of multiple sclerosis (MS). In the European Union, Gilenya is indicated for adult patients with high disease activity despite treatment with at least one disease modifying agent, or evolving severe relapsing-remitting MS. Exelon (rivastigmine tartrate) and Exelon Patch (rivastigmine transdermal system) are cholinesterase inhibitors indicated for the treatment of Alzheimer's disease (AD) dementia and Parkinson's disease (PD) dementia.
The Company's Established Medicines include Diovan, Exforge, Voltaren/Cataflam and Ritalin, Ritalin LA, Focalin and Focalin XR. Diovan (valsartan), together with Diovan HCT/Co-Diovan (valsartan and hydrochlorothiazide), is an angiotensin II receptor blocker (ARB) and is an anti-hypertensive medications around the world. Exforge (valsartan and amlodipine besylate) is a single-pill combination of the ARB Diovan and the calcium channel blocker amlodipine besylate. Voltaren/Cataflam (diclofenac sodium/potassium/resinate/free acid) is a non-steroidal anti-inflammatory drug (NSAID) for the relief of symptoms in rheumatic diseases, such as rheumatoid arthritis and osteoarthritis, and for various other inflammatory and pain conditions. Ritalin, Ritalin LA, Focalin and Focalin XR (methylphenidate hydrochloride (HCl), methylphenidate HCl extended release, dexmethylphenidate HCl and dexmethylphenidate HCl extended release) are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children. Ritalin LA and Focalin XR are additionally indicated for ADHD in adults. Ritalin is also indicated for narcolepsy.
The Company's Alcon segment develops, manufactures and sells eye care products around the world. Alcon is engaged in eye care and offers a range of products serving the lifecycle of patient needs across eye diseases, vision conditions and refractive errors. Alcon products are available in approximately 180 markets.
The Company's Alcon segment's Surgical franchise is engaged in providing ophthalmic surgical product, offering ophthalmic surgical equipment, instruments, disposable products and intraocular lenses for surgical procedures that address cataracts, vitreoretinal conditions, glaucoma and refractive errors. Alcon's Surgical portfolio includes the Cataract Refractive Suite by Alcon, Infiniti vision system to perform cataract surgeries, which is the phacoemulsification platform, the Constellation vision system for retinal operations, and the WaveLight refractive suite for refractive procedures and Lasik treatments. Alcon also offers the AcrySof family of intraocular lenses (IOLs) to treat cataracts, including the AcrySof IQ, AcrySof IQ PanOptix, AcrySof IQ Toric and AcrySof IQ ReSTOR Toric IOLs. In addition, Alcon provides advanced viscoelastics, surgical solutions, surgical packs and other disposable products for cataract and vitreoretinal surgery.
The Company's Alcon segment's Ophthalmic Pharmaceuticals franchise develops and sells a range of pharmaceuticals to treat chronic and acute conditions of the eye, including glaucoma, elevated intraocular pressure (associated with glaucoma), eye infection and inflammation, eye allergies, dry eye and retinal diseases. Ophthalmic Pharmaceuticals also oversees the line of over-the-counter (OTC) brands that include artificial tears and ocular vitamins. The Ophthalmic Pharmaceuticals portfolio includes Ilevro ophthalmic suspension for the treatment of pain and inflammation associated with cataract surgery; Simbrinza suspension to lower intraocular pressure as a fixed-dose combination; Azopt, Azarga, Travatan Z and DuoTrav, each ophthalmic solutions for the treatment of elevated intraocular pressure associated with open-angle glaucoma or ocular hypertension; Vigamox ophthalmic solution for bacterial conjunctivitis; Pazeo and Pataday ophthalmic solution for ocular itching associated with allergic conjunctivitis; Nevanac ophthalmic suspension for eye pain and inflammation following cataract surgery and to reduce the risk of macular edema associated with cataract surgery in diabetic patients; the Systane family of over-the-counter products for dry eye relief, and Jetrea intravitreal injection for treating vitreomacular traction.
The Company's Alcon segment Vision Care franchise develops and sells contact lenses and lens care products. Alcon's portfolio of silicone hydrogel, daily disposables and color contact lenses includes its Air Optix, Dailies and Freshlook brands. Its Dailies product line includes Dailies Total1 lenses, a water gradient contact lens. Its Air Optix product line includes the Air Optix Colors silicone hydrogel contact lenses. Its contact lens care solutions business includes the Opti-Free line of multi-purpose disinfecting solutions and drops, as well as the Clear Care and AOSept Plus hydrogen peroxide lens care solutions.
Sandoz is organized into three franchises around the globe: Retail Generics, Anti-Infectives and Biopharmaceuticals & Oncology Injectables. In Retail Generics, Sandoz develops, manufactures and markets active ingredients and finished dosage forms of pharmaceuticals to third parties. Retail Generics includes the specialty areas of Dermatology, Respiratory and Ophthalmics, as well as cardiovascular, metabolism, central nervous system, pain, gastrointestinal and hormonal therapies.
In Anti-Infectives, Sandoz manufactures active pharmaceutical ingredients and intermediates, mainly antibiotics for internal use by Retail Generics and for sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein or other biotechnology-based products (known as biosimilars or follow-on biologics) and provides biotechnology manufacturing services to other companies, and in Oncology Injectables, Sandoz develops, manufactures and markets cytotoxic products for the hospital market.
Company Web Links
- Novartis CEO plays down prospects for Actelion bid: Blick
- Novartis says 82 percent of leukemia patients in remission after CAR-T
- Biotech group Actelion, Johnson & Johnson confirm deal talks
- Johnson & Johnson approaches Actelion about takeover deal
- UPDATE 4-Johnson & Johnson approaches Actelion about takeover deal